The future of cancer treatment: will it include immunotherapy?


Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells. 
DOI: 10.1016/j.ccr.2012.06.009


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.